Explore the latest advances in biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD). Stay informed about these key tools for diagnosis and management.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease, affecting a staggering 30% of the global population.
Currently, there are rising levels of non-alcoholic fatty liver disease (NAFLD). With this, comes a concurrent increase in hepatocellular carcinoma (HCC) cases.
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of non-alcoholic steatohepatitis (NASH).
Research into personalised medicine for non-alcoholic fatty liver disease (NAFLD) underscores the importance of acknowledging NAFLD patients’ unique clinical phenotypes when developing targeted pharmacotherapies.
Liver-related events contribute to a small proportion of mortality within the collective cohort of patients with non-alcoholic fatty liver disease (NAFLD).
Recent research supports the existence of a potential link between non-alcoholic fatty liver disease (NAFLD) and fatty pancreas.
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways.
Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Hepatocytic ballooning is characterised by hepatocyte degeneration identifiable through an enlarged, swollen and rounded cellular phenotype with a distinctly reticulated cytoplasm.
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Non-alcoholic fatty liver disease (NAFLD) is a major contributor to liver-related illnesses and fatalities worldwide. Its clearly established two-way connection with obesity, a significant public health issue showing increasing prevalence rates globally and regionally, necessitates comprehensive education focused on NAFLD and the implementation of worldwide policies to address it effectively.
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.